Effect of Estrogen Treatment and Vitamin D Status on Differing Bioavailabilities of Calcium Carbonate and Calcium Citrate
| Autor: | Howard J. Heller, Beverley Adams-Huet, John R. Poindexter |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class Biological Availability chemistry.chemical_element Calcium Calcium Carbonate chemistry.chemical_compound Pharmacokinetics Oral administration Internal medicine medicine Vitamin D and neurology Humans Drug Interactions Pharmacology (medical) Vitamin D Aged Randomized Controlled Trials as Topic Retrospective Studies Aged 80 and over Pharmacology Cross-Over Studies Estrogens Middle Aged Drug interaction Bioavailability Postmenopause Drug Combinations Endocrinology Calcium carbonate chemistry Estrogen Female Calcium Citrate |
| Zdroj: | The Journal of Clinical Pharmacology. 42:1251-1256 |
| ISSN: | 0091-2700 |
| DOI: | 10.1177/009127002762491343 |
| Popis: | The authors hypothesized that estrogen treatment or vitamin D status may affect the bioavailability of two common calcium supplements differently. Using data derived from a recent trial in 25 postmenopausal women, the authors found that deltaAUC of serum calcium after subtraction of placebo was significantly higher after calcium citrate (median, 0.85; 25th to 75th percentile, 0.70 to 3.15) than after calcium carbonate (0.25; -0.58 to 1.00) in non-estrogen-treated patients. There was no difference in the bioavailability of calcium between the two calcium formulations in estrogen-treated patients. Bioavailability was also significantly higher with the citrate salt for the subgroups with lower serum 25-hydroxyvitamin D and higher serum 1,25-dihydroxyvitamin D concentrations. In summary, bioavailability of calcium from the calcium carbonate product was more dependent on estrogen treatment and vitamin D status than that of calcium citrate. This may explain the variable results of reported calcium supplementation studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text